Jia N, Zhang G, Sun X, et al. - Researchers investigated how angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are associated with the risk of mortality as well as other clinical outcomes in patients suffering from COVID-19. PubMed, Medline, EMBASE, ClinicalTrials, TRIP, the Cochrane Library, CNKI, Wanfang, and CBM database were explored. They found and analyzed 28 studies with 73 465 patients. Findings showed absence of an association of ACEIs/ARBs with the risk of in-hospital all-cause death in COVID-19 patients, however, a reduced risk of 30-day all-cause mortality may be conferred by ACEIs/ARBs. The results indicated that the use of ACEIs/ARBs may be beneficial for patients with hypertension.